Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.
This study shows that state-of-the-art liquid chromatography (LC) and mass spectrometry (MS) can be used for rapid verification of identity and characterization of sequence variants and posttranslational modifications (PTMs) for antibody products. A candidate biosimilar IgG1 monoclonal antibody (mAb) was compared in detail to a commercially available innovator product. Intact protein mass, primary sequence, PTMs, and the micro-differences between the two mAbs were identified and quantified simultaneously. Although very similar in terms of sequences and modifications, a mass difference observed by LC-MS intact mass measurements indicated that they were not identical. Peptide mapping, performed with data independent acquisition LC-MS using an alternating low and elevated collision energy scan mode (LC-MS(E)), located the mass difference between the biosimilar and the innovator to a two amino acid residue variance in the heavy chain sequences. The peptide mapping technique was also used to comprehensively catalogue and compare the differences in PTMs of the biosimilar and innovator mAbs. Comprehensive glycosylation profiling confirmed that the proportion of individual glycans was different between the biosimilar and the innovator, although the number and identity of glycans were the same. These results demonstrate that the combination of accurate intact mass measurement, released glycan profiling, and LC-MS(E) peptide mapping provides a set of routine tools that can be used to comprehensively compare a candidate biosimilar and an innovator mAb.
Xie
Hongwei
H
Waters Corporation.
Chakraborty
Asish
A
Waters Corporation.
Ahn
Joomi
J
Waters Corporation.
Yu
Ying Qing
YQ
Waters Corporation.
Dakshinamoorthy
Deepalakshmi P
DP
Waters India Pvt. Ltd.
Gilar
Martin
M
Waters Corporation.
Chen
Weibin
W
Waters Corporation.
Skilton
St John
SJ
Waters Corporation.
Mazzeo
Jeffery R
JR
Waters Corporation.
D000595:Amino Acid Sequence; D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000235:genetics*; D059451:Biosimilar Pharmaceuticals / Q000737:chemistry; D002853:Chromatography, Liquid / Q000379:methods*; D055808:Drug Discovery / Q000379:methods*; D014644:Genetic Variation / Q000235:genetics; D006031:Glycosylation; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry / Q000235:genetics*; D007167:Immunotherapy / Q000379:methods*; D062069:Inventions; D013058:Mass Spectrometry; D010449:Peptide Mapping; D011134:Polysaccharides / Q000737:chemistry; D012984:Software; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D059451:Biosimilar Pharmaceuticals; D007074:Immunoglobulin G; D011134:Polysaccharides; D000068878:Trastuzumab
Eur J Biochem. 1979 Sep;99(2):323-31
387413
J Am Soc Mass Spectrom. 2008 Nov;19(11):1643-54
18707900
Protein Sci. 1993 Mar;2(3):331-8
8453372
Eur J Biochem. 1977 Feb;72(3):443-52
320001
Anal Chem. 2006 Sep 15;78(18):6645-50
16970346
Nat Biotechnol. 2007 Feb;25(2):145-6
17287732
Rapid Commun Mass Spectrom. 2005;19(16):2331-6
16041822
Mol Cell Proteomics. 2006 Jan;5(1):144-56
16219938
Proteomics. 2009 Mar;9(6):1683-95
19294628
Nat Rev Drug Discov. 2009 Mar;8(3):226-34
19247305
J Am Soc Mass Spectrom. 2009 Nov;20(11):2021-33
19744865
Trends Pharmacol Sci. 2009 Jul;30(7):356-62
19552968
J Chromatogr B Biomed Sci Appl. 2001 Mar 10;752(2):233-45
11270864
Anal Chem. 2005 Sep 15;77(18):6004-11
16159134
Curr Pharm Biotechnol. 2008 Dec;9(6):482-501
19075687
J Biol Chem. 1982 Mar 25;257(6):3018-25
6277922
Curr Pharm Biotechnol. 2008 Dec;9(6):423-30
19075682
Mass Spectrom Rev. 2007 May-Jun;26(3):370-88
17410555
Pharm Res. 1989 Nov;6(11):903-18
2687836
Curr Pharm Biotechnol. 2008 Dec;9(6):421-2
19075681
Anal Chem. 2008 Dec 15;80(24):9491-8
19072263
N Engl J Med. 2008 Mar 13;358(11):1109-17
18337601
J Pept Res. 2004 May;63(5):437-48
15140161
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 25;819(2):203-18
15833284
MAbs. 2009 Sep-Oct;1(5):394-416
20065643
Anal Chem. 2005 Apr 1;77(7):2187-200
15801753
Anal Chem. 2009 Jul 15;81(14):5699-708
19518054
Nat Biotechnol. 2008 Sep;26(9):962-3
18779793
Rapid Commun Mass Spectrom. 2007;21(5):730-44
17279597
Protein Sci. 1999 Nov;8(11):2519-23
10595558
Pharm Res. 1994 May;11(5):764-71
8058650
J Proteome Res. 2006 Apr;5(4):1003-9
16602709
Anal Biochem. 2009 Sep 15;392(2):145-54
19497295
J Biopharm Stat. 2010 Jan;20(1):46-61
20077248
Science. 2006 Aug 4;313(5787):670-3
16888140
Biochemistry. 1989 Feb 7;28(3):1377-84
2713370
MAbs. 2009 Jul-Aug;1(4):332-8
20073133
Pharmacogenet Genomics. 2009 May;19(5):383-7
19319024
Pharm Res. 1992 Nov;9(11):1386-93
1475223
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Feb 1;878(3-4):403-8
20036624
Anal Biochem. 2009 Sep 1;392(1):12-21
19457431
Nat Rev Drug Discov. 2009 Mar;8(3):181
19247295